Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $3.33 Average PT from Brokerages

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $3.3333.

CGTX has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 4th. Brookline Capital Acquisition upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Brookline Cap M raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Finally, Wall Street Zen raised shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Institutional Investors Weigh In On Cognition Therapeutics

A number of large investors have recently added to or reduced their stakes in CGTX. Raymond James Financial Inc. boosted its position in Cognition Therapeutics by 34.7% during the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after acquiring an additional 7,641 shares in the last quarter. Bryn Mawr Trust Advisors LLC lifted its stake in shares of Cognition Therapeutics by 69.1% in the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after purchasing an additional 16,129 shares during the period. Jones Financial Companies Lllp purchased a new position in shares of Cognition Therapeutics in the 3rd quarter valued at approximately $25,000. Gamco Investors INC. ET AL bought a new stake in shares of Cognition Therapeutics during the third quarter valued at approximately $27,000. Finally, Private Management Group Inc. purchased a new stake in Cognition Therapeutics in the third quarter worth $32,000. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Price Performance

Shares of CGTX stock opened at $1.06 on Thursday. The stock has a market capitalization of $93.57 million, a price-to-earnings ratio of -2.21 and a beta of 1.25. The company’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $1.57. Cognition Therapeutics has a 1 year low of $0.22 and a 1 year high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. Equities research analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current year.

Cognition Therapeutics News Roundup

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CGTX to “Strong‑Buy” and released a set of quarterly and full‑year EPS estimates that are less negative than market consensus (Brookline FY2026: -$0.46 vs. consensus -$0.80). The upgrade plus narrower loss estimates likely improved investor expectations for future valuation and financing needs. Brookline coverage (MarketBeat)
• Positive Sentiment: Cognition extended the duration of its expanded access program (EAP) for Zervimesine (CT1812) in dementia with Lewy bodies, allowing enrolled patients additional months of treatment — a sign of ongoing clinical engagement and potential real‑world data generation that can de‑risk the program incrementally. GlobeNewswire: EAP extension
• Neutral Sentiment: Multiple Brookline research notes repeated the same forward‑looking quarterly estimates (Q4‑2025 through Q4‑2026) and the Strong‑Buy call — the breadth of published estimates helps set expectations but adds little new detail beyond the upgrade. Brookline coverage (MarketBeat)
• Negative Sentiment: Despite the more favorable forecasts from Brookline, Cognition remains a clinical‑stage company with no approved products and ongoing projected losses (consensus FY current year ~ -$0.80 EPS). That keeps the stock exposed to clinical, regulatory and financing risk, which can drive volatility and dilution. Market context (MarketBeat)

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.